FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2160879594> ?p ?o ?g. }

• W2160879594 endingPage "385" @default.
• W2160879594 startingPage "380" @default.
• W2160879594 abstract "Our objective was to verify the efficacy and safety of docetaxel + 5-fluorouracil + cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer.Between January and November 2002, we enrolled 43 patients [males 31; median age 55 years (range 24-74)] with inoperable gastric cancer who had not been seen previously in Seoul National University Hospital. The regimen used was docetaxel 70 mg/m(2) on day 1, cisplatin 40 mg/m(2) on days 2 and 3, and 5-fluorouracil 1200 mg/m(2) over 10 h on days 1-3, every 3 weeks.A total of 168 cycles were administered. Mean cycle number per patient was 3.9. The administered dose intensity of docetaxel was 21.23 mg/m(2)/week, 5-FU 1092.14 mg/m(2)/week and cisplatin 23.82 mg/m(2)/week, which corresponded to 91.1, 91.0 and 89.5% of planned doses. Of the 43 patients, response evaluation was possible in 40 and, of these patients, 17 (42.5%) achieved a partial response, 13 (32.5%) stable disease, and 10 patients (25%) showed progressive disease. The median time to progression was 5.6 months [95% confidence interval (CI) 4.6-6.6 months]. Median overall survival was 9.0 months. (95% CI 4.8-13.2 months). Leukopenia occurred during 21.4% of cycles (36 of 168 cycles); 14.3% grade 1, 5.3% grade 2 and 1.8% grade 3. Anemia occurred in 16.7% (28 of 168 cycles); 11.3% grade 1, 4.8% grade 2 and 0.6% grade 3. Thrombocytopenia was not observed. Diarrhea, stomatitis and hypersensitivity occurred in 4.7% (two out of 43 patients), respectively. Neutropenic fever occurred in two patients (4.7%) and myalgia in three (7.0%).Docetaxel + 5-fluorouracil + cisplatin 3-day combination chemotherapy is an active and tolerable regimen as a first-line treatment in patients with unresectable gastric cancer." @default.
• W2160879594 created "2016-06-24" @default.
• W2160879594 creator A5000302975 @default.
• W2160879594 creator A5009933828 @default.
• W2160879594 creator A5019037704 @default.
• W2160879594 creator A5024891671 @default.
• W2160879594 creator A5041556537 @default.
• W2160879594 creator A5043202113 @default.
• W2160879594 creator A5050684671 @default.
• W2160879594 creator A5059766169 @default.
• W2160879594 creator A5072696954 @default.
• W2160879594 creator A5082375033 @default.
• W2160879594 date "2005-06-23" @default.
• W2160879594 modified "2023-10-05" @default.
• W2160879594 title "Docetaxel + 5-Fluorouracil + Cisplatin 3-day Combination Chemotherapy as a First-line Treatment in Patients with Unresectable Gastric Cancer" @default.
• W2160879594 cites W1833555732 @default.
• W2160879594 cites W1974734959 @default.
• W2160879594 cites W1982559524 @default.
• W2160879594 cites W1984795042 @default.
• W2160879594 cites W1989399468 @default.
• W2160879594 cites W1992408996 @default.
• W2160879594 cites W1994913124 @default.
• W2160879594 cites W2015051818 @default.
• W2160879594 cites W2057282119 @default.
• W2160879594 cites W2130522735 @default.
• W2160879594 cites W2141048526 @default.
• W2160879594 cites W2144208072 @default.
• W2160879594 cites W2145340852 @default.
• W2160879594 cites W2164011084 @default.
• W2160879594 cites W2170346929 @default.
• W2160879594 cites W2185943375 @default.
• W2160879594 cites W2237190276 @default.
• W2160879594 cites W2313318623 @default.
• W2160879594 cites W4243323729 @default.
• W2160879594 doi "https://doi.org/10.1093/jjco/hyi107" @default.
• W2160879594 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15976069" @default.
• W2160879594 hasPublicationYear "2005" @default.
• W2160879594 type Work @default.
• W2160879594 sameAs 2160879594 @default.
• W2160879594 citedByCount "14" @default.
• W2160879594 countsByYear W21608795942012 @default.
• W2160879594 countsByYear W21608795942013 @default.
• W2160879594 countsByYear W21608795942014 @default.
• W2160879594 countsByYear W21608795942016 @default.
• W2160879594 countsByYear W21608795942018 @default.
• W2160879594 crossrefType "journal-article" @default.
• W2160879594 hasAuthorship W2160879594A5000302975 @default.
• W2160879594 hasAuthorship W2160879594A5009933828 @default.
• W2160879594 hasAuthorship W2160879594A5019037704 @default.
• W2160879594 hasAuthorship W2160879594A5024891671 @default.
• W2160879594 hasAuthorship W2160879594A5041556537 @default.
• W2160879594 hasAuthorship W2160879594A5043202113 @default.
• W2160879594 hasAuthorship W2160879594A5050684671 @default.
• W2160879594 hasAuthorship W2160879594A5059766169 @default.
• W2160879594 hasAuthorship W2160879594A5072696954 @default.
• W2160879594 hasAuthorship W2160879594A5082375033 @default.
• W2160879594 hasBestOaLocation W21608795941 @default.
• W2160879594 hasConcept C121608353 @default.
• W2160879594 hasConcept C126322002 @default.
• W2160879594 hasConcept C141071460 @default.
• W2160879594 hasConcept C2776694085 @default.
• W2160879594 hasConcept C2777063308 @default.
• W2160879594 hasConcept C2778239845 @default.
• W2160879594 hasConcept C2778248108 @default.
• W2160879594 hasConcept C2778336483 @default.
• W2160879594 hasConcept C2778822529 @default.
• W2160879594 hasConcept C2780456651 @default.
• W2160879594 hasConcept C2780873365 @default.
• W2160879594 hasConcept C2781190966 @default.
• W2160879594 hasConcept C2781413609 @default.
• W2160879594 hasConcept C71924100 @default.
• W2160879594 hasConcept C90924648 @default.
• W2160879594 hasConceptScore W2160879594C121608353 @default.
• W2160879594 hasConceptScore W2160879594C126322002 @default.
• W2160879594 hasConceptScore W2160879594C141071460 @default.
• W2160879594 hasConceptScore W2160879594C2776694085 @default.
• W2160879594 hasConceptScore W2160879594C2777063308 @default.
• W2160879594 hasConceptScore W2160879594C2778239845 @default.
• W2160879594 hasConceptScore W2160879594C2778248108 @default.
• W2160879594 hasConceptScore W2160879594C2778336483 @default.
• W2160879594 hasConceptScore W2160879594C2778822529 @default.
• W2160879594 hasConceptScore W2160879594C2780456651 @default.
• W2160879594 hasConceptScore W2160879594C2780873365 @default.
• W2160879594 hasConceptScore W2160879594C2781190966 @default.
• W2160879594 hasConceptScore W2160879594C2781413609 @default.
• W2160879594 hasConceptScore W2160879594C71924100 @default.
• W2160879594 hasConceptScore W2160879594C90924648 @default.
• W2160879594 hasIssue "7" @default.
• W2160879594 hasLocation W21608795941 @default.
• W2160879594 hasLocation W21608795942 @default.
• W2160879594 hasOpenAccess W2160879594 @default.
• W2160879594 hasPrimaryLocation W21608795941 @default.
• W2160879594 hasRelatedWork W13394025 @default.
• W2160879594 hasRelatedWork W2094938224 @default.
• W2160879594 hasRelatedWork W2119557593 @default.
• W2160879594 hasRelatedWork W2211675861 @default.
• W2160879594 hasRelatedWork W2348123719 @default.
• W2160879594 hasRelatedWork W2360017634 @default.

• next